1-7 of 7
Kae Hashimoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Yasuto Kinose, Kenjiro Sawada, Hiroshi Makino, Tomonori Ogura, Tomoko Mizuno, Noriko Suzuki, Tomoyuki Fujikawa, Eiichi Morii, Koji Nakamura, Ikuko Sawada, Aska Toda, Kae Hashimoto, Aki Isobe, Seiji Mabuchi, Tsuyoshi Ohta, Akiko Itai, Ken-ichirou Morishige, Hirohisa Kurachi, Tadashi Kimura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (4): 909–919.
https://doi.org/10.1158/1535-7163.MCT-14-0696
Published: 09 April 2015
View article titled, IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
Open the PDF for IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment in another window
Includes: Supplementary data
Journal Articles

Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis

Giulio Francia, Yuval Shaked, Kae Hashimoto, John Sun, Melissa Yin, Carolyn Cesta, Ping Xu, Shan Man, Christina Hackl, Julie Stewart, Mark Uhlik, Anne H. Dantzig, F. Stuart Foster, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 680–689.
https://doi.org/10.1158/1535-7163.MCT-11-0659
Published: 06 March 2012
View article titled, Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
Open the PDF for Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis in another window
Includes: Multimedia, Supplementary data
Journal Articles

Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

Kae Hashimoto, Shan Man, Ping Xu, William Cruz-Munoz, Terence Tang, Rakesh Kumar, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (4): 996–1006.
https://doi.org/10.1158/1535-7163.MCT-09-0960
Published: 07 April 2010
View article titled, Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Open the PDF for Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer in another window
Journal Articles

Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

Kae Hashimoto, Shan Man, Ping Xu, William Cruz‐Munoz, Terence Tang, Anthony Mutsaers, Rakesh Kumar, Robert S. Kerbel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A9.
https://doi.org/10.1158/1535-7163.TARG-09-A9
Published: 10 December 2009
View article titled, Abstract A9: Potent preclinical impact of metronomic low‐dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
Journal Articles

Fasudil-induced hypoxia-inducible factor-1α degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells

Keiko Takata, Ken-ichirou Morishige, Toshifumi Takahashi, Kae Hashimoto, Seiji Tsutsumi, Limei Yin, Tsuyoshi Ohta, Jun Kawagoe, Kazuhiro Takahashi, Hirohisa Kurachi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (6): 1551–1561.
https://doi.org/10.1158/1535-7163.MCT-07-0428
Published: 19 June 2008
View article titled, Fasudil-induced hypoxia-inducible factor-1α degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells
Open the PDF for Fasudil-induced hypoxia-inducible factor-1α degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells in another window
Journal Articles

Fasudil inhibits lysophosphatidic acid-induced invasion of ovarian cancer cells

Seiji Ogata, Ken-ichirou Morishige, Kenjirou Sawada, Kae Hashimoto, Seiji Mabuchi, Chiaki Kawase, Masahiro Sakata, Tadashi Kimura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B196.
Published: 01 November 2007
View article titled, Fasudil inhibits lysophosphatidic acid-induced invasion of ovarian cancer cells
Journal Articles

Fasudil inhibits vascular endothelial growth factor–induced angiogenesis in vitro and in vivo

Limei Yin, Ken-ichirou Morishige, Toshifumi Takahashi, Kae Hashimoto, Seiji Ogata, Seiji Tsutsumi, Keiko Takata, Tsuyoshi Ohta, Jun Kawagoe, Kazuhiro Takahashi, Hirohisa Kurachi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (5): 1517–1525.
https://doi.org/10.1158/1535-7163.MCT-06-0689
Published: 18 May 2007
View article titled, Fasudil inhibits vascular endothelial growth factor–induced angiogenesis <em>in vitro</em> and <em>in vivo</em>
Open the PDF for Fasudil inhibits vascular endothelial growth factor–induced angiogenesis <em>in vitro</em> and <em>in vivo</em> in another window